NUMAB
Numab is a biotechnology company that offers antibody-based therapeutics for the treatment of severe diseases such as chronic inflammation and cancer. It features a plug-and-play platform that substantially reduces the random nature of the discovery process to predictably yield ready-to-develop multispecific biotherapeutics.
NUMAB
Industry:
Biopharma Biotechnology Health Care Health Diagnostics Life Science Medical Therapeutics
Founded:
2011-01-01
Address:
Wadenswil, Zurich, Switzerland
Country:
Switzerland
Website Url:
http://www.numab.com
Total Employee:
11+
Status:
Active
Contact:
41445330471
Email Addresses:
[email protected]
Total Funding:
122 M CHF
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Content Delivery Network Google Universal Analytics
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
ARNA Genomics
ARNA Genomics is a biotechnology company that specializes in developing fluid biopsy technology.
Beta Bugs
Beta Bugs is a cutting edge biotechnology company that produces enhanced insect strains for the growing insect farming industry.
Biomnigene
Biomnigene is a biotechnology agency that offers DNA/RNA extraction to microbiome analysis and research services.
Demetrix
Demetrix is a biotechnology company dedicated to researching and producing bioactive ingredients.
Genomics
Genomics plc aiming to lead the genomic transformation of healthcare.
Imago BioSciences
Imago is a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs).
Libre Foods
Libre Foods is a biotech startup on a mission to liberate the food system and create a more free future for people, the planet and animals.
Oxitec
Oxitec develops an environment-friendly technology for the control of significant insect pests to prevent diseases and agricultural damage.
Current Advisors List
Current Employees Featured
Founder
Investors List
Cormorant Asset Management
Cormorant Asset Management investment in Series C - Numab
HBM Partners
HBM Partners investment in Series C - Numab
BlackRock
BlackRock investment in Series C - Numab
Forbion Capital Partners
Forbion Capital Partners investment in Series C - Numab
HBM Healthcare Investments AG
HBM Healthcare Investments AG investment in Series C - Numab
RTW Investments LLC
RTW Investments LLC investment in Series C - Numab
BVF Partners
BVF Partners investment in Series C - Numab
Novo Holdings
Novo Holdings investment in Series C - Numab
Octagon Capital Advisors
Octagon Capital Advisors investment in Series C - Numab
3sbio
3sbio investment in Series B - Numab
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2019-12-12 | 3sbio | Numab investment in Post-IPO Equity - 3sbio | 15 M CHF |
Official Site Inspections
http://www.numab.com Semrush global rank: 8.83 M Semrush visits lastest month: 245
- Host name: 212.243.197.113
- IP address: 212.243.197.113
- Location: Onex Switzerland
- Latitude: 46.1877
- Longitude: 6.0981
- Timezone: Europe/Zurich
- Postal: 1213
More informations about "Numab" on Search Engine
Numab Therapeutics AG | About us
Informed. numab, Drug Innovators, Swiss biotech company, development, antibody-based therapeutics, Swiss, biotech company, biotech, antibody, antibodies, antibody fragment, scFv, variable domain, Fv fragment, antibody discovery, antibody development, drug, drug discovery, drug development, high-affinity, high affinity, drug-like, highly stable ...See details»
Numab Therapeutics AG
Advancing a proprietary pipeline of next generation immunology and immuno-oncology drugs. Establishing leading platform of next generation plug & play novel multispecific therapeutics. ©. numab, Drug Innovators, Swiss biotech company, development, antibody-based therapeutics, Swiss, biotech company, biotech, antibody, antibodies, antibody ...See details»
Numab Therapeutics AG | Pipeline
We are building a pipeline of highly differentiated multi-specific drug discovery and development programs based on our unique ฮป-Capโข & MATCHโข proprietary technologies. Numab is striving to overcome historical drug discovery barriers and build a pipeline of first-in-class and best-in-class medicines for patients suffering from serious ...See details»
Numab - Crunchbase Company Profile & Funding
Numab is a biotechnology company that offers antibody-based therapeutics for the treatment of severe diseases such as chronic inflammation and cancer. It features a plug-and-play platform that substantially reduces the random nature of the discovery process to predictably yield ready-to-develop multispecific biotherapeutics.See details»
Numab Therapeutics AG | LinkedIn
About us. Numab Therapeutics is developing multi-specific antibody-based immunotherapies for inflammation and cancer.See details»
Numab and Eisai Enter Into a Global Research and Option โฆ
Oct 1, 2019 TOKYO & ZURICH-- ( BUSINESS WIRE )--Numab Therapeutics AG (Numab) today announced the initiation of a partnership with Eisai, Co., Ltd (Eisai), under a research and option agreement, to...See details»
Numab Therapeutics and Ono Pharmaceutical Announce an
HORGEN, Switzerland, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Numab Therapeutics AG (โNumabโ) and Ono Pharmaceutical Co., Ltd. (โOnoโ) today announced a global research, development and...See details»
Numab Therapeutics secures $110m in Series C funding round
May 21, 2021 A Switzerland-based clinical-stage biopharmaceutical company, Numab focuses on developing multi-specific antibody immunotherapies for cancer and inflammation. Numab plans to use the funds to speed up the clinical development of its lead programme, NM21-1480, for various cancer types.See details»
Numab Therapeutics Completes Oversubscribed CHF 100 Million โฆ
May 20, 2021 WAEDENSWIL, Switzerland-- ( BUSINESS WIRE )--Numab Therapeutics AG, a clinical stage biopharmaceutical company developing next-generation multispecific antibody-based immunotherapies for...See details»
Numab - Contacts, Employees, Board Members, Advisors
Organization. Numab. Connect to CRM. Save. Summary Financials People Technology Signals & News Similar Companies. Highlights. Employee Profiles 6. Number of Board Member and Advisor Profiles 7. Contacts 7. About. Numab has 6 current employee profiles, including CSO, and Co-CEO, Founder David Urech.See details»
Numab Therapeutics Company Profile: Valuation, Funding
Mar 9, 2020 Numab Therapeutics Overview. Update this profile. Year Founded. 2011. Status. Private. Latest Deal Type. Series C. Latest Deal Amount. $105M. Investors. 14. General Information. Description. Operator of a biopharmaceutical company intended to develop multispecific antibody-based immunotherapies.See details»
Numab Therapeutics Announces First Subject Dosed in Phase 1 โฆ
May 15, 2023 HORGEN, Switzerland-- ( BUSINESS WIRE )-- Numab Therapeutics AG (Numab), a clinical stage biotechnology company advancing a proprietary pipeline of immunology and oncology therapeutics,...See details»
Numab Therapeutics: First patient dosed in clinical study to โฆ
Aug 24, 2020 Numab Therapeutics AG announced today the first patient has been dosed in its proprietary ND021 program, a next-generation tri-specific immuno-oncology approach targeting PD-L1, 4-1BB and Serum Albumin.See details»
Numab Therapeutics and Ono Pharmaceutical Announce an
HORGEN, Switzerland, Feb. 14, 2024 (GLOBE NEWSWIRE) -- (โNumabโ) and Ono Pharmaceutical Co., Ltd. (โOnoโ) today announced a global research, development and commercialization collaboration for...See details»
Numab - Funding, Financials, Valuation & Investors - Crunchbase
CHF122M. in funding over 3 rounds. Their latest funding was raised on Dec 5, 2022 from a Series C round. Numab is funded by 12 investors. HBM Healthcare Investments AG and Cormorant Asset Management are the most recent investors. Numab has invested in 3SBio Inc. on Dec 12, 2019.See details»
Numab Therapeutics and Ono Pharmaceutical Announce an โฆ
HORGEN, Switzerland, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Numab Therapeutics AG (โNumabโ) and Ono Pharmaceutical Co., Ltd. (โOnoโ) today announced a global research, development and...See details»
ONO Enters into a Development and License Agreement with Numab
Mar 31, 2022 In March 2020, Ono expanded the alliance with Numab by entering into a second research and option agreement to discover and develop a distinct multispecific antibody drug candidates, other than those covered by this agreement, for the treatment of various cancers.See details»
Numab Therapeutics AG | News
Mar 31, 2022 News. October 19, 2023 Numab Therapeutics Announces First Patient Dosed in Phase 1 Multiple Ascending Dose (MAD) Study of NM26 for Moderate to Severe Atopic Dermatitis. Read more. May 15, 2023 Numab Therapeutics Announces First Subject Dosed in Phase 1 Clinical Study of NM26 Program. Read more.See details»
Numab Therapeutics AG โ Swiss Biotech
Bachtobelstrasse 5, 8810 Horgen, Switzerland. Get Directions. Canton. Zurich. Facts & figures. Type of organization. Private company. Year of foundation. 2011. Number of employees in Switzerland. 50-149. Key business. R&D. Core competencies. Therapeutics/vaccines (human) R&D. Member. 4051 Basel.See details»
Numab Therapeutics and Ono Pharma Partner To Develop Multi โฆ
Feb 15, 2024 Numab Therapeutics AG, an organization creating multi-explicit antibody-based immunotherapies for irritation and cancer disease, and Osaka-settled Research and development situated drug organization, Ono Pharma, both mutually declared a worldwide examination, improvement and commercialization joint effort for NM49, a multi-specific โฆSee details»